
|Videos|July 8, 2011
Dr. Whelan Discusses the MA.20 Trial's Survival Findings
Author(s)Timothy J. Whelan, BM, BCh
Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings
Advertisement
Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, discusses the various survival benefits found in the NCIC-CTG MA.20 intergroup phase III trial that randomized 1832 breast cancer patients to receive either whole-breast irradiation (WBI) or WBI plus regional nodal irradiation (RNI). Patients that received both RNI and WBI saw a disease-free survival of nearly 90% but failed to meet the primary endpoint of overall survival.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5




































